After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
For the FLU-IVIG trial, researchers evaluated the safety and efficacy of anti-influenza hyperimmune intravenous immunoglobulin to better understand the clinical benefits for patients with influenza.
While it is known that disease progression of HIV-1 is delayed by HIV-2 in coinfected individuals, authors of a new study sought to identify the protective mechanisms of the coinfection.
With the aging HIV population, it is important to understand how inflammation and age-related comorbidities will affect treatment options in this population moving forward. This was the topic of Tuesday’s...
Results of a new study presented at CROI 2019, found the efficacy and safety of F/TAF versus F/TDF for PrEP in MSM and transgender women who are at high risk of HIV acquisition.
In this plenary session, Alexandra M. Oster, from the CDC, discusses molecular detection of HIV clusters, how the United States has used that data, and how researchers have responded to these clusters. ...
For his Bernard Fields Lecture at CROI 2019, Dr Michel C. Nussenzweig from the Rockefeller University in New York discussed the discovery and development of HIV broadly neutralizing antibodies.
While weight gain occurs after ART initiation with all modern regimens, researchers of a study presented at CROI 2019 determined whether INSTI-based ART is associated with excess weight gain.
In Thursday’s Plenary Session at CROI 2019, David Blast, from the University of Liverpool highlighted the drug interactions in the older HIV population, the need for more searchable databases, and which...
